Literature DB >> 18251579

National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures.

Kodela Vani1, Seshi R Sompuram, Patrick Fitzgibbons, Steven A Bogen.   

Abstract

CONTEXT: An important component in fostering test standardization for HER2 testing by immunohistochemistry is an appropriate positive control. We developed a new standardized, quantitative immunohistochemical HER2 control using a HER2 peptide covalently attached to glass microscope slides. The peptide controls can be formalin fixed or unfixed, providing the new capability of distinguishing errors associated with antigen retrieval from errors associated with the staining process itself.
OBJECTIVE: To investigate the causes of variability in HER2 immunohistochemistry staining performance. By comparing laboratory performance with both formalin-fixed and unfixed analyte controls, we aimed to distinguish problems associated with antigen retrieval from reagent or staining protocol deficiencies.
DESIGN: HER2 peptide analyte controls were printed on 2 slides that also contained unstained sections of invasive breast carcinomas and were mailed with the College of American Pathologists' 2006 HER2-B proficiency testing survey. Laboratory participants were asked to stain the 2 slides and return them for central review and quantification. This study is unique in combining central review with new quantitative HER2 controls.
RESULTS: Of 109 participants who returned evaluable stained slides, staining was suboptimal in 20 (18.3%) as judged by quantification of the peptide analyte controls and review of tissue sections. Of those, 35% failed due to antigen retrieval errors, 20% failed due solely to antibody or staining protocol problems, and the remainder failed due to a combination of the two.
CONCLUSIONS: In practice, errors in HER2 testing are caused by variables associated with antigen retrieval and the reagents and staining protocol, as well as interpretive error. Analyte controls help distinguish these different causes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251579     DOI: 10.5858/2008-132-211-NHPTRU

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  12 in total

1.  Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems.

Authors:  Seshi R Sompuram; Kodela Vani; Brian Tracey; Debra A Kamstock; Steven A Bogen
Journal:  J Histochem Cytochem       Date:  2015-05-04       Impact factor: 2.479

2.  Experimental validation of peptide immunohistochemistry controls.

Authors:  Steven A Bogen; Kodela Vani; Brian McGraw; Vin Federico; Iqbal Habib; Ron Zeheb; Ed Luther; Colin Tristram; Seshi R Sompuram
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-05

Review 3.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

4.  Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations.

Authors:  Sharenda L Williams; George G Birdsong; Cynthia Cohen; Momin T Siddiqui
Journal:  Int J Clin Exp Pathol       Date:  2009-01-20

5.  Molecular mechanisms of antigen retrieval: antigen retrieval reverses steric interference caused by formalin-induced cross-links.

Authors:  S A Bogen; K Vani; S R Sompuram
Journal:  Biotech Histochem       Date:  2009-10       Impact factor: 1.718

6.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Regine M Schoenherr; Ping Yan; Kimberly Allison; Melissa Shipley; Melissa Lerch; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  J Proteome Res       Date:  2016-07-27       Impact factor: 4.466

7.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

8.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

9.  Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.

Authors:  Sabina Berezowska; Alexander Novotny; Karina Bauer; Annette Feuchtinger; Julia Slotta-Huspenina; Karen Becker; Rupert Langer; Axel Walch
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240

10.  Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.

Authors:  Zsuzsanna Varga; Aurelia Noske; Constanze Ramach; Barbara Padberg; Holger Moch
Journal:  BMC Cancer       Date:  2013-12-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.